Bandi e concorsi
Graduatoria concorso 2016
Graduatoria finale
Titolo progetto
|
Merito
|
CV e struttura
|
Punteggio finale
|
Paroxysmal Nocturnal Hemoglobinuria related thrombosis: descending from the top of the iceberg.
|
16
|
15.8
|
31.8
|
Epigenetic alterations of the microenvironment in therapy-related myeloid neoplasms.
|
21
|
16.9
|
37.9
|
Plasmonic exosomes for enhanced monitoring of Monoclonal Gammopathy of Undetermined Significance.
|
13
|
11.8
|
24.8
|
Molecular basis and prognostication of Secondary Myelofibrosis.
|
24
|
2.9
|
26.9
|
Minimal Residual Disease detection by quantitative PCR in Mantle Cell Lymphoma: prospective evaluation of patients enrolled in a large, multicenter clinical trial.
|
16
|
11.1
|
27.1
|
Targeting hematopoietic stem cells expansion in CEBPA mutant AML.
|
17
|
13.9
|
30.9
|
Clinical and laboratory characterization of platelet dysfunction caused by Ibrutinib treatment in patients with Chronic Lymphocytic Leukemia and potential reversal by Desmopressin administration.
|
28
|
10
|
38
|
Transferrin Receptor Type 2 and Erythropoietin Receptor in myelodysplastic syndromes: two new possible prognostic indicators of response to erythropoietin and erythropoiesis stimulating agent treatments.
|
23
|
14
|
37
|
The genome of diffuse large B-cell lymphomas associated with HCV infection.
|
14
|
10.5
|
24.5
|
Elucidating the functional in vivo role of BOCR mutation in Acute Myeloid Leukemia.
|
18
|
14
|
32
|
Precise diagnosis in T-acute lymphoblastic leukemia (T-ALL). Translation of new results from research to diagnostic tests.
|
23
|
14.4
|
37.4
|
The prognostic impact of subclonal TP53 gene mutations detected by next generation sequencing in good risk chronic lymphocytic leukemia (CLL) patients.
|
5
|
9
|
14
|
The inhibition of the DNA damage response pathway using Bosutinib isomer (Bos-I) as a novel treatment for Acute Lymphoblastic Leukemia.
|
23
|
13
|
36
|
Erythroblastemia and other effects in natalizumab-treated patients.
|
15
|
10.3
|
25.3
|
Use of platelets as siRNA vectors for silencing the BCR-ABL fusion gene in chronic myeloid leukemia (CML).
|
27
|
11.3
|
38.3
|
Myc-related metabolism in Acute Myeloid Leukemia
|
23
|
10
|
33
|
Identification of Genomic Aberrations in Acute Myeloid Leukemia (AML) patients by Single Nucleotide Polymorphism Microarray (SNP) Approache.
|
9
|
12.3
|
21.3
|
I ricorsi sono ammessi entro 3 giorni dalla data di pubblicazione della presente graduatoria.
I commenti sono disabilitati.
|